𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The subcommissural organ expresses D2, D3, D4, and D5dopamine receptors

✍ Scribed by Mercedes Tomé; Antonio J. Jiménez; Hans Richter; Karin Vio; F. Javier Bermúdez-Silva; Esteban M. Rodríguez; Jose Manuel Pérez-Fígares


Publisher
Springer-Verlag
Year
2004
Tongue
English
Weight
679 KB
Volume
317
Category
Article
ISSN
0302-766X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


D2 and D4 dopamine receptor polymorphism
✍ Noble, Ernest P.; Ozkaragoz, Tulin Z.; Ritchie, Terry L.; Zhang, Xuxian; Belin, 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

The relationship of various dimensions of temperament, measured by the Tridimensional Personality Questionnaire (TPQ), to polymorphisms of the D2 dopamine receptor (DRD2) and D4 dopamine receptor (DRD4) genes was determined in 119 healthy Caucasian boys who had not yet begun to consume alcohol and o

Evolution and expression of D2 and D3 do
✍ Wendy Boehmler; Sophie Obrecht-Pflumio; Victor Canfield; Christine Thisse; Berna 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 892 KB

## Abstract We mined the zebrafish genomic sequence database and identified contigs containing segments of several dopamine receptor genes. By using a polymerase chain reaction amplification strategy, we generated full‐length cDNAs encoding a single dopamine D3 receptor and three distinct D2 recept

5-HT2C (HTR2C)serotonin receptor gene po
✍ Ebstein, Richard P.; Segman, Ronnen; Benjamin, Jonathan; Osher, Yamima; Nemanov, 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

We recently reported an association between the long repeat allele of the dopamine D4 exon III receptor polymorphism and a human personality dimension, novelty seeking, as measured by the tridimensional personality questionnaire (TPQ), a personality instrument designed by Cloninger to reflect herita

Antiparkinsonian effects of the novel D3
✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept